{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T12:54:25Z","timestamp":1773492865262,"version":"3.50.1"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Neopharma Japan Co., Ltd.","award":["no"],"award-info":[{"award-number":["no"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Mitochondrial diabetes mellitus (MDM) is characterized by maternal inheritance, progressive neurosensory deafness, insulin secretory disorder, and progressive microvascular complications. Mitochondria are critical organelles that provide energy in the form of adenosine triphosphate (ATP). An impairment of ATP production in pancreatic \u03b2 cells is regarded as the main cause of the insulin secretory disorder in patients with MDM, and these patients require insulin replacement therapy early after the diagnosis. The amino acid 5-aminolevulinic acid (5-ALA), a precursor of heme metabolites, is a non-proteinogenic \u03b4 amino acid synthesized in mitochondria. An addition of ferrous iron to 5-ALA enhances heme biosynthesis and increases ATP production through an upregulation of the respiratory complex. Several studies have reported that the administration of 5-ALA and ferrous iron to existing treatment improved the glycemic control in both patients with prediabetes and those with type 2 diabetes mellitus. The additional administration of 5-ALA and ferrous iron to MDM patients on insulin therapy may improve their insulin secretory capacity and glycemic control by improving their mitochondrial function. The findings of this study are expected to provide new treatment options for MDM and improve the patients\u2019 glycemic control and prognosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods\/design:<\/jats:title>\n            <jats:p>This study is a single-arm, open-label pilot intervention study using clinical endpoints to investigate the effects of treatment with 5-ALA plus sodium ferrous citrate (SFC) to patients with MDM on their glucose tolerance. A total of 5 patients with MDM will be administered 5-ALA\/SFC (200\u200amg\/d) for 24\u200aweeks. We will perform a 75-g oral glucose tolerance test before and at 24\u200aweeks after the start of this 5-ALA\/SFC treatment to evaluate glucose-dependent insulin responses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion:<\/jats:title>\n            <jats:p>To the best of our knowledge, this study will be the first assessment of the effects of 5-ALA\/SFC in patients with MDM. This study will obtain an evidence regarding the effectiveness and safety of 5-ALA\/SFC for patients with MDM.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration:<\/jats:title>\n            <jats:p>This study was registered with the University Hospital Medical Information Network (UMIN000040581) on July 1, 2020 and with the Japan Registry of Clinical Trials (jRCTs071200025) on August 3, 2020.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000025100","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T01:02:04Z","timestamp":1615510924000},"page":"e25100","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["A single-arm, open-label, intervention study to investigate the improvement of glucose tolerance after administration of the 5-aminolevulinic acid (5-ALA) in the patients with mitochondrial diabetes mellitus"],"prefix":"10.1097","volume":"100","author":[{"given":"Yuta","family":"Nakamura","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Nagasaki University Hospital"},{"name":"Department of Endocrinology and Metabolism, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Haraguchi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Nagasaki University Hospital"},{"name":"Department of Endocrinology and Metabolism, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riyoko","family":"Shigeno","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Nagasaki University Hospital"},{"name":"Department of Endocrinology and Metabolism, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Nagasaki University Hospital"},{"name":"Department of Endocrinology and Metabolism, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Horie","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Nagasaki University Hospital"},{"name":"Department of Endocrinology and Metabolism, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Nagasaki University Hospital"},{"name":"Department of Endocrinology and Metabolism, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Abiru","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Nagasaki University Hospital"},{"name":"Department of Endocrinology and Metabolism, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0168-8227(02)00246-2","article-title":"Clinical features of diabetes mellitus with the mitochondrial DNA 3243 (A-G) mutation in Japanese: maternal inheritance and mitochondria-related complications","volume":"59","author":"Suzuki","year":"2003","journal-title":"Diabetes Res Clin Pract"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1056\/NEJM199404073301403","article-title":"A subtype of diabetes mellitus associated with a mutation of mitochondrial DNA","volume":"330","author":"Kadowaki","year":"1994","journal-title":"N Engl J Med"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1056-8727(99)00060-4","article-title":"Mitochondrial DNA mutations are associated with both decreased insulin secretion and advanced microvascular complications in Japanese diabetic subjects","volume":"13","author":"Fukuda","year":"1999","journal-title":"J Diabetes Complications"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7326\/0003-4819-134-9_Part_1-200105010-00008","article-title":"Maternally inherited diabetes and deafness: a multicenter study","volume":"134","author":"Guillausseau","year":"2001","journal-title":"Ann Intern Med"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2337\/diabetes.47.3.374","article-title":"Effects of depletion of mitochondrial DNA in metabolism secretion coupling in INS-1 cells","volume":"47","author":"Kennedy","year":"1998","journal-title":"Diabetes"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1756-0500-4-66","article-title":"The effect of 5-aminolevulinic acid on cytochrome c oxidase activity in mouse liver","volume":"4","author":"Ogura","year":"2011","journal-title":"BMC Res Notes"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1752-8062.2012.00421.x","article-title":"Use of the dietary supplement 5-aminiolevulinic acid (5-ALA) and its relationship with glucose levels and hemoglobin A1C among individuals with prediabetes","volume":"5","author":"Rodriguez","year":"2012","journal-title":"Clin Transl Sci"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.nut.2013.02.008","article-title":"5-aminolevulinic acid, a precursor of heme, reduces both fasting and postprandial glucose levels in mildly hyperglycemic subjects","volume":"29","author":"Higashikawa","year":"2013","journal-title":"Nutrition"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"415","DOI":"10.31989\/ffhd.v4i9.151","article-title":"Safety test of a supplement, 5-aminolevulinic acid phosphate with sodium ferrous citrate, in diabetic patients treated with oral hypoglycemic agents","volume":"4","author":"Yamashita","year":"2014","journal-title":"Funct Food Health Dis"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"8294805","DOI":"10.1155\/2016\/8294805","article-title":"The safety and tolerability of 5-aminolevulinic acid phosphate with sodium ferrous citrate in patients with type 2 diabetes mellitus in Bahrain","volume":"2016","author":"Al-Saber","year":"2016","journal-title":"J Diabetes Res"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Ann Intern Med"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/35008121","article-title":"Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage","volume":"404","author":"Nishikawa","year":"2000","journal-title":"Nature"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2337\/diabetes.55.01.06.db05-0943","article-title":"Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells","volume":"55","author":"Kukidome","year":"2006","journal-title":"Diabetes"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"10549","DOI":"10.1038\/s41598-019-46772-x","article-title":"Effects of 5-aminolevulinic acid and sodium ferrous citrate on fibroblasts from individuals with mitochondrial diseases","volume":"9","author":"Shimura","year":"2019","journal-title":"Sci Rep"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/2211-5463.12048","article-title":"Combination of 5-aminolevulinic acid and ferrous ion reduces plasma glucose and hemoglobin A1c levels in Zucker diabetic fatty rats","volume":"6","author":"Hara","year":"2016","journal-title":"FEBS Open Bio"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40360-016-0108-3","article-title":"5-aminolevulinic acid combined with ferrous ion reduces adiposity and improves glucose tolerance in diet-induced obese mice via enhancing mitochondrial function","volume":"18","author":"Ota","year":"2017","journal-title":"BMC Pharmacol Toxicol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:03:25Z","timestamp":1746338605000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":18,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000025100","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,12]]},"assertion":[{"value":"2021-02-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}